A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Azintuxizumab-vedotin (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 01 Jun 2017 Status changed from active, no longer recruiting to discontinued.
- 05 May 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2016 Planned End Date changed from 1 Apr 2019 to 1 May 2019.